بدائل البحث:
values decrease » values increased (توسيع البحث), largest decrease (توسيع البحث)
large decrease » marked decrease (توسيع البحث), large increases (توسيع البحث), large degree (توسيع البحث)
i values » _ values (توسيع البحث)
i large » _ large (توسيع البحث), a large (توسيع البحث), via large (توسيع البحث)
values decrease » values increased (توسيع البحث), largest decrease (توسيع البحث)
large decrease » marked decrease (توسيع البحث), large increases (توسيع البحث), large degree (توسيع البحث)
i values » _ values (توسيع البحث)
i large » _ large (توسيع البحث), a large (توسيع البحث), via large (توسيع البحث)
-
1
-
2
-
3
Bivariate analysis of predisposing factors associated with increased risk of death within 30 days.
منشور في 2024"…<p>Bivariate analysis of predisposing factors associated with increased risk of death within 30 days.</p>…"
-
4
-
5
Adjusted hazard ratio for 30-day mortality demonstrating adjusted associations between SCAI shock stages with 30-day mortality.
منشور في 2022الموضوعات: "…stepwise significant increase…"
-
6
-
7
-
8
-
9
-
10
-
11
Independent predictors of 30-day mortality.
منشور في 2024"…The mean duration of VA-ECMO support was 6 days (interquartile range 4–7 days). The 30-day mortality was 50.8%. …"
-
12
-
13
-
14
-
15
-
16
-
17
-
18
Proportion of T cells with Treg Phenotype increases from pre-infusion to day 7.
منشور في 2022الموضوعات: -
19
Forest plot: Mortality (follow-up: 30 days).
منشور في 2025"…</p><p>Results</p><p>We found 7 RCTs (n = 3053). The PS, compared to fibrinolysis alone, may have an important reduction on mortality (3.3% vs 3.9%; −5 per 1000; 95% CI: −16 to +10); and has an important reduction on reinfarction (2.6% vs 4.4%; −19 per 1000; 95% CI: −27 to −6), revascularization (9.0% vs 26.8%; −169 per 1000; 95% CI: −220 to −64), and recurrent ischemia (1.2% vs 5.7%; −46 per 1000; 95% CI: −52 to −27) at 30 days follow up. …"
-
20
Forest plot: Reinfarction (follow-up: 30 days).
منشور في 2025"…</p><p>Results</p><p>We found 7 RCTs (n = 3053). The PS, compared to fibrinolysis alone, may have an important reduction on mortality (3.3% vs 3.9%; −5 per 1000; 95% CI: −16 to +10); and has an important reduction on reinfarction (2.6% vs 4.4%; −19 per 1000; 95% CI: −27 to −6), revascularization (9.0% vs 26.8%; −169 per 1000; 95% CI: −220 to −64), and recurrent ischemia (1.2% vs 5.7%; −46 per 1000; 95% CI: −52 to −27) at 30 days follow up. …"